Use of Cilostazol, a Novel Antiplatelet Agent, in a Post-Palmaz-Schatz Stenting Regimen

We evaluated the therapeutic efficacy of cilostazol, a novel potent inhibitor of phosphodiesterase, for the prevention of stent thrombosis following implantation of a Palmaz-Schatz stent guided by angiographic visual estimation alone in 71 patients with 84 lesions. Patients received 81 mg of aspirin 3 times daily and 100 mg of cilostazol twice daily after angiographic confirmation of optimal Palmaz-Schatz stent implantation. Of the 84 vessels stented, 65 (77%) were classified as type B2 or C lesions according to the modified American Heart Association/American College of Cardiology classification, and 51 (61%) were <3.0 mm in diameter. Multiple stents were used in 26 patients (31%). The final balloon inflation pressure was 18.3 ± 1.5 atm. The balloon-to-vessel ratio was 1.18 ± 0.16. No patient received heparin or warfarin after the procedure. There were no deaths, Q-wave myocardial infarctions, in- or out-of-hospital stent thrombosis, coronary bypass surgery, or serious side effects such as neutropenia and/or liver dysfunction during the 1-month follow-up period. These results indicate that cilostazol was a safe and effective antiplatelet agent with minimum side effects after Palmaz-Schatz stent implantation. luated the usefulness of cilostazol, a novel antiplatelet agent, for the prevention of stent thrombosis. No deaths, Q-wave myocardial infarctions, stent thrombosis, or serious side effects such as neutropenia occurred during the 1-month follow-up period, which suggests cilostazol is a safe and effective antiplatelet agent after Palmaz-Schatz stent implantation.